1. Falanga A, Tickles FR. Pathophysiology of the thrombotic state in the cancer patient. Semin Thromb Haemostas.1999; 25: 173–82.
2. Green KB, Silverstein RL. Hypercoagulability in cancer. Hemat Onc Clin North AM 1996; 10: 499–530.
3. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting. 2005; 13–17: 748–577.
4. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force Report. European Society of Cardiology. Europ Heart J 2000; 21: 1301–36.
5. Turkstra F, Koopman MM, Buller HR. The treatment of deep vein thrombosis and pulmonary embolism. Thromb Haemost 1997; 78: 489–96.
6. Hull RD, Brand RF, Pineo GF et al. Preoperative vs postoperative initiation of low molecular weight heparin prophilaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159: 137–41.
7. Баркаган З.С., Цывкина Л.П., Момот А.П., Шилова А.Н. Ошибки, просчеты и пути совершенствования клинического применения низкомолекулярных гепаринов. Клин. фармакол. и тер. 2000; 11 (1): 78–83.
8. Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. JHT 2005; 3 (8): 1554–60.
9. Hyers TM, Agnelii G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (Suppl. 1): 176.